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drug doses above couceutratious correspoudiug to this occupancy, impairmeiit i i i family fmictioiiiiig (but iiot occupatioiial or social 
have limited beneficial effects. Finally, the occupancy found in fuuctiouiug) was higher wheu there was somatoform disorder or 
the auimal models correlates with those published for humaus in alcohol abuse comorbidity. The linear relation betweeu impair- 
a PET study of citalopram aud paroxetiue using the SERT ligaud meut aud munber of positive DSM items add to the evidence 
DASB2,iudicatiug that the doses used in our auimal studies are found in the literature that the distiuctiou betweeu miuor aud major 
cliiiically relevaiit. depression is rather artificial. 
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Objectives: 1) Evaluatiou of impairment in occupational, social 
aud family fuuctiouiug in primary care patients with a diagnosis 
of Major Depressive Disorder (MDD) by DSM-IV criteria aud 
by PHQ; 2) Iuvestigatiug whether impairment iucreases in a 
(dis)coutiuuous way with iucreasiug number of positive DSM 
items (or iucreasiug munber of positive PHQ items) for MDD. 
Methods: Patients with clinical diagnosis of major depression 
were included in the study. After iuclusiou PCPs completed a 
list with DSM-IV criteria for MDD aud patients completed the 
differeut modules of the PHQ, a self-report version of PRIME- 
MD (1). In addition the Sheehan Disability Scales aud the SCL90 
were completed. 
Results: Among a total of 1072 patients who were considered 
as evaluable for baseline-analysis, 969 (90%) were diagnosed 
with MDD by the physician On basis of the patieut’ s self- 
diagnosis (PHQ) ouly 668 (68%) had MDD. Results 011 Sheehan 
Scales showed that impainneut scores were always (for subsequent 
groups with 5, 6, 7, 8 or 9 positive DSM items) higher for 
social fuuctiouiug aud family fuuctiouiug thau for occupational 
fuuctiouiug. A statistically siguificaut gender effect (p=O.O06) 
was observed, women having higher scores 011 the Sheehan 
item ‘impainneut in family fuuctiouiug’ (even wheu correcting 
for professional activity) but lower scores 011 the Sheehan item 
‘impainneut in occupational functioning’ In this large group of 
patients with MDD, impainneut decreased with age (piO.0001) 
aud patients living alone had higher Sheehan scores for impair- 
meut in social fuuctiouiug (p=O.O02). Associated complaints 011 
PHQ: Comorbidity of somatofonn disorder, panic disorder aud 
alcohol abuse was found in respectively 42%, 29% aud 16% of 
the patients. Women had a higher risk (p=O.OOS) 011 somatofonn 
disorder thau meu (OR= 1.5) aud the impainneut in family fuuc- 
tiouiug was higher wheu a somatofonn disorder or alcohol abuse 
was diagnosed. After aualysiug the relation betweeu impainneut 
aud munber of positive DSM items we found a linear iucrease 
in impainneut with iucreasiug munber of positive DSM items 
for the three impainneut items (occupational, social, aud family 
fuuctiouiug), suggesting that the discrimiuatiou betweeu miuor 
aud major depression is artificial. 
Conclusions: Impainneut in this group of patients with MDD 
was moderate to severe (most scores betweeu 5 aud 8 011 the Shee- 
hau Disability Scale). The impainneut was higher for social aud 
family fuuctiouiug thau for occupational fuuctiouiug. Moreover, 
IP.1.1721 Bright light therapy in seasonal affective 
disorder - does it suffice? 
E. Pjrek, D. Wiukler, A. Koustautiuidis, N. Thierry, A. Heideu, 
S. Kasper. University of Vienna, Department of General 
Psychiatry, Vienna, Austria 
Objectives: Seasonal affective disorder (SAD) is defined as a fonn 
of recurreut depressive or bipolar affective disorder characterized 
by recurreut affective episodes that occur amnrally at the same 
time of the year @asper et al., 1988). Guideliues for SAD 
have proposed bright light therapy (BLT) as the treatment of 
choice (Tennau et al., 1989). H owever couveutioual autidepressaut 
treatment has also beeu found to be effective in this couditiou 
(Kasper et al., 2001). The aim of this iuvestigatiou was to assess 
the importance of drug treatment in a clinical sample of SAD 
patients. 
Methods: We examined the psychopharmacologic treatment of 
578 outpatients (446 females, 132 males) suffering from SAD 
(uuipolar depression: 77.9%, bipolar-II disorder: 19.6%, bipolar-I 
disorder: 2.2%) that had beeu treated with BLT at the Department 
of General Psychiatry (University of Viemla). 
Results: 47.9% of all patients received psychopharmacologic 
treatment in addition to BLT. 34.6% were treated with autidepres- 
sauts (24.9% SSRI [selective serotouiu reuptake inhibitors], 6.6% 
NaSSA [noradrenergic aud specific serotouergic autidepressauts], 
5.2% tricyclic autidepressauts, 3.3% tetracyclic autidepressauts, 
1.4% SNRI [serotouiu aud uoradreualiu reuptake inhibitors], 
1.2% RIMA [reversible iuhibitors of mouoamiuoxydase A], 0.2% 
NARI [noradrenalin reuptake inhibitors]), 5.2% received phase 
prophylaxis with lithium or autiepileptics, 9.0% were treated 
with auxiolytic substances (mostly beuzodiazepiues), 7.6% with 
phytophannaceutical medication (7.4% hypericum extract, 0.5% 
valeriau extract), 3.3% with typical ueuroleptics, 1.0% with atyp- 
ical ueuroleptics, 3.3% with other medication No significant 
differences in medication were observed in regard to gender, age, 
duration of hospitalizatiou or munber of affective episodes. Pa- 
tieuts suffering from bipolar disorder received phase prophylactic 
medication more frequently (bipolar-I: 38.5%, bipolar-II: 8.0%) 
thau patients with uuipolar depression (3.6%; Likelihood ratio 
e-2=17.591, df=3, p=O.OOOS). 
Conclusions: A substantial part (about oue third) of our patients 
was treated with autidepressaut medication coucomitaut to BLT. 
Obviously BLT does uot suffice as ouly autidepressaut regime11 
for all SAD patients. Opposed to the guidelines for the treatment 
of depression patients with several depressive episodes did uot 
receive autidepressaut long-tenn medication or phase prophylaxis 
more ofteu thau patients with ouly a few episodes. Our results 
also show, that the majority of patients with bipolar disorder still 
does uot receive auy phase prophylactic medication, which could 
indicate the ueed for further treatment. 
